Kala Pharmaceuticals - Raised $115M Funding from 16 investors

Nov 5, 2024 · Kala Pharmaceuticals has raised a total funding of $115M over 11 rounds from 16 investors. Investors include Athyrium Capital Management, Vivo Capital and 14 others. Their …

CouponFollow Extension

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Nov 5, 2024 · Kala Pharmaceuticals has raised a total funding of $115M over 11 rounds from 16 investors. Investors include Athyrium Capital Management, Vivo Capital and 14 others. Their …

tracxn.com

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Kala Pharmaceuticals has raised a total funding of $115M over 10 rounds from 16 investors. Investors include Polaris Partners, Orbimed and 14 others. Their latest funding round was of …

tracxn.com

$11
OFF

Investors Cough Up $11.5M For Kala Pharmaceuticals

1 week from now

Kala Pharmaceuticals, a Waltham, MA-based developer of treatments for diseases affecting mucosal tissues, has secured $11.5 million in Series A financing. The company will use the …

pitchbook.com

$115
OFF

Kala Pharmaceuticals - Company Profile - Tracxn

1 week from now

Oct 22, 2024 · Kala Pharmaceuticals - Developer of ophthalmic treatments based on its mucosal penetrating product platform. Public Company. Raised a total funding of $115M over 11 …

tracxn.com

$16122541
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $16122541 on 2021-11-29 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$11
OFF

Kala Pharmaceuticals Inks $11.5M In Series A - VC News Daily

1 week from now

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, announced today …

vcnewsdaily.com

$18
OFF

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2020 ...

1 week from now

Feb 25, 2021 · Kala anticipates that its cash resources as of December 31, 2020, together with anticipated INVELTYS revenue and the $18.2 million in net proceeds raised in January 2021 …

kalarx.com

$31
OFF

Kala Pharmaceuticals Announces Up To $31 Million Private …

1 week from now

Nov 28, 2022 · Under the terms of the agreement, Kala has agreed to sell in a first tranche an aggregate of 76,813 shares of its common stock at a price of $5.75 per share and an …

yahoo.com

$5.48
OFF

Kala Pharmaceuticals Competitors And Alternatives - Tracxn

1 week from now

Oct 22, 2024 · Kala Pharmaceuticals's competitors have raised a total of $5.48B funding across 332 funding rounds. See the distribution of funded competitors of Kala Pharmaceuticals below. …

tracxn.com

$1.21
OFF

Kala - Company Profile - Tracxn

1 week from now

Nov 5, 2024 · Kala ranks 33rd among 357 active competitors. 71 of its competitors are funded while 36 have exited. Overall, Kala and its competitors have raised over $1.21B in funding …

tracxn.com

FAQs about Kala Pharmaceuticals - Raised $115M Funding from 16 investors Coupon?

How many investors does Kala pharmaceuticals have?

Kala Pharmaceuticals has 15 investors including Oxford Finance LLC and Athyrium Capital Management LP. How much funding has Kala Pharmaceuticals raised to date? Kala Pharmaceuticals has raised . When was the last funding round for Kala Pharmaceuticals? Kala Pharmaceuticals closed its last funding round on Nov 28, 2022 from a Post-IPO Equity round. ...

What does Kala pharmaceuticals do?

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, ...

When did Kala pharmaceuticals close?

Kala Pharmaceuticals closed its last funding round on Nov 28, 2022 from a Post-IPO Equity round. Who are Kala Pharmaceuticals 's competitors? Alternatives and possible competitors to Kala Pharmaceuticals may include Amylyx Pharmaceuticals , Akebia Therapeutics , and PhaseBio Pharmaceuticals. ...

How does Kala improve drug distribution and pharmacokinetics?

The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, Which industries do these Sub-Organization operate in? Where is Kala Pharmaceuticals 's headquarters? ...

Where is Kala pharmaceuticals located?

Kala Pharmaceuticals is located in Waltham, Massachusetts, United States. Who invested in Kala Pharmaceuticals? Kala Pharmaceuticals has 15 investors including Oxford Finance LLC and Athyrium Capital Management LP. How much funding has Kala Pharmaceuticals raised to date? ...

What are alternatives to Kala pharmaceuticals?

Alternatives and possible competitors to Kala Pharmaceuticals may include Amylyx Pharmaceuticals , Akebia Therapeutics , and PhaseBio Pharmaceuticals. Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues. ...